Biogen Idec Inc (BIIB) 318.78 $BIIB Acorda 2Q Earnings &

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2015 at 2:48 AM

Biogen Idec Inc (BIIB) 318.78 $BIIB

Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 2:43PM CDT
Acorda (ACOR) narrowed its 2015 guidance for Ampyra to $410 million - $420 million from $405 million - $420 million.
BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMAG: 63.90 (-0.87), ACOR: 34.36 (+0.13)

Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)

Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 8:38AM CDT
Investing in biotech stocks can be very intimidating for beginners, as many investors consider the word "biotech" to be synonymous with "risk". Press releases are filled with scientific jargon, many companies are losing money, and normal valuation...
BIIB: 318.78 (+1.78)

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)

Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)

Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 318.78 (+1.78), F: 14.83 (-0.27), RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), AMGN: 176.59 (+4.90), DD: 55.76 (+0.17), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), UPS: 102.36 (+0.96), CELG: 131.25 (-0.63)

5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 78.32 (+3.08), ZINC: 8.28 (+0.21), BIIB: 318.78 (+1.78), MJN: 88.39 (-1.09), DPZ: 113.84 (unch)

Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 318.78 (+1.78)

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04)

Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"

(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 318.78 (+1.78)

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)

Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 318.78 (+1.78), TEVA: 69.02 (-0.05)

3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)

Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 318.78 (+1.78)

'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), BIIB: 318.78 (+1.78), ISIS: 54.93 (+1.76), MDSO: 53.80 (-0.22), COP: 50.34 (-1.73), SNDK: 60.29 (-0.26)

Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), AMZN: 536.15 (-0.61), BIIB: 318.78 (+1.78), MDLZ: 45.13 (-0.14), EA: 71.55 (-0.75), SNA: 164.80 (+0.42), NKE: 115.22 (+0.21), MDSO: 53.80 (-0.22), FB: 94.01 (-1.20), FCX: 11.75 (-0.09), COP: 50.34 (-1.73), DIS: 120.00 (-0.03), NFLX: 114.31 (+2.75), ISIS: 54.93 (+1.76), QLIK: 40.46 (-0.04), KHC: 79.47 (+0.26), GOOGL: 657.50 (-7.06), ULTA: 166.03 (-0.79), CMCSA: 62.41 (+0.05), GIS: 58.21 (-0.05), SNDK: 60.29 (-0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Metriport Eyes Major Step in Health Data Integration

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Chad Tucker's Sequel Explores Deep Spiritual Themes

An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...

EnGenius Names Experienced VP to Boost Sales Growth

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

WareSpace Expands Reach With $36.5M Acquisitions

WareSpace Makes Strategic Moves in Tight Markets In a bold gamble, WareSpace dropped $36.5 million to snag fresh industrial real estate in Miami Gardens, Florida, and South San Francisco, California. These aren't random picks, mind you. They're strategic grabs in markets where finding space ain't easier than winning the lottery. With more than 210 flexible units for small...

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

EmpowHer Grants Propel Female-led Social Ventures Forward

Every now and then, you stumble upon a story that makes you take off your trading hat and put on your 'citizen of the world' one. The Boundless Futures Foundation is doing just that, pushing past the $1.5 million mark in grant funding to back female founders creating real scale impact. If this doesn't sound like a nonprofit turning the gears of change, I don't know what...